20 PMBLs, five cHL (L428, L1236, HDLM-2, KM-H2, and L540) and two PMBL cell lines (MedB-1 and Karpas1106) for presence of the activating V617F mutation in the JAK2 gene by sitespecific restriction analysis ( Figure 1a ).
Chromosomal translocations between the immunoglobulin heavy chain locus (IGH) and different oncogenes, are a genetic hallmark of human B-cell malignancies. 1 The development of sensitive PCR methods has recently revealed that such translocations can be also recurrently found at low frequencies in peripheral blood mononuclear cells (PBMNC) from many healthy individuals in absence of clinical manifestation. 2 Particular interest focused on the t(14;18)(q32;q21) translocation, which is strongly associated with 85-90% of follicular lymphoma (FL) and represents one of the most common abnormalities in non-Hodgkin's lymphoma (NHL). The t(14;18) translocation, arising from the illegitimate joining between the BCL2 proto-oncogene and the IGH locus, and the subsequent block of apoptotic cell death are believed to constitute early events in the pathogenesis of FL. The t(14;18) translocation has been reported in PBMNC of healthy adults with a prevalence going from 8 to 80% mainly depending on the PCR technology used. 2 The frequency of circulating t(14;18)-bearing cells usually vary between 1 in 10 5 and 1 in 10 7 normal cells and multiple translocations can co-exist in single individuals. However, the relationship between t(14;18) in healthy individuals and progression to disease is still unclear. Particularly, the long-term evolution of t(14;18)-carrying cells remains largely unknown. The detailed understanding of its evolution in healthy individuals is the key both to gain insights into the pathogenic steps involved in tumor progression, and to adequate usage as a potential early biomarker for lymphoma. Current available data is limited to short-term follow-up studies with a persistence of the t(14;18) for few months in only some individuals. 3 We recently complemented those data by analyzing a larger population of healthy individuals sampled twice on a 4-month interval reporting both a stable frequency of t(14;18)-positive cells and the maintenance of identical BCL2-IGH clones. 4 Therefore, to address the question of the long-term follow-up, we have performed a longitudinal study on the same healthy population after a three-year period, and investigated the evolution and features of the t(14;18) translocation in peripheral blood from 26 individuals (mean: 42.5, age: 27-59 years). To detect and quantify the t(14;18)-bearing cells, a sensitive fluctuation nested PCR analysis of the IGH/BCL2 der(14) breakpoint (30 repetitions per sample) was performed for each time point on DNA extracted from PBMNC, and the frequency was estimated using a Poisson's model, as previously described. 4 Most PCR products were sequenced and sequences were compared with the GenBank database using BLAST program to identify BCL2 and IGH breakpoint positions, DH, JH regions, and the intervening region sequence.
For the present study, 3-years follow-up matched samples were available for 26 subjects (Table 1) . Comparison of the occurrence of the translocation at the two time points (P0 w/s and P3 s ) revealed a nonsignificant increase in prevalence (14/26 at P0 w/s vs 20/26 at P3 s , P ¼ 0.07, Fisher's test). This increase in prevalence was accompanied by a significant increase in the mean frequency of the translocation (evolving from 3.8 Â 10 À6 to 5.8 Â 10
À6
, P ¼ 0.03), suggesting not only persistence but also accumulation of t(14;18) overtime at the population level. At the individual level, t(14;18) frequency was unchanged for four individuals (15.4%), increased for 15 (57.6%) and decreased or dropped below the detection limit for seven individuals (27%) (Figure 1) . The relationships between age and translocation frequency has been reported before in several transversal studies, including ours. 2, 4 For the first time, however, the present longitudinal approach gave us the opportunity to directly investigate the effect of ageing on frequency evolution with multiple assessments of the same subject at different time points. As the observations (t(14;18) detection) within one individual are interrelated, correlation between all paired time points must, therefore, be integrated into a statistical model that takes into account the association between the measurements. A Generalized Estimating Equations model (GEE) was thus calculated as follows:
where Y ij ¼ frequency for individual i at period j and x ij ¼ age the year of sampling, with a normal distribution. 5 The GEE final model indicated that ageing was one prevalent parameter which significantly accounts for frequency evolution over this 3 years time frame (P ¼ 0.0031). This indicates that the overall raise in t(14;18) rates is not due to a major clonal expansion in few individuals, but rather to a tendency to slow increase and a constant persistence of the translocation in most individuals overtime.
Is this overall evolution mainly due to the occurrence of new translocations or to the persistence and/or expansion of Figure 1 Pattern of t(14;18) frequency evolution in PBMNC from 26 healthy individuals during a three year period (P0 w and/or P0 s and P3 s ). A logarithm representation of the t(14;18) frequency (y-axis) is plotted vs age (x-axis). For each paired samples, frequency data are linked by a line. Increased frequency is indicated by a continuous line (n ¼ 15), decreased frequency by a thin dotted line (n ¼ 7), and maintenance of a stable level by a thick dotted line (n ¼ 4). The initial frequency level was calculated from our previously report performed on the same population. For undetectable samples, a frequency of 4.24 Â 10 À7 (half detection limit) was arbitrary assigned. a BCL2-MBR locus divided into six classes entitled 1a,1b,2a,2b,3a and 3b, as previously described. 7 Nucleotide positions are indicated between brackets and numbered according to the published BCL2 cDNA sequence (M14745). Letters to the Editor pre-existing clones? In our previous report, we observed the presence within most individuals of multiple different BCL2-IGH junctions. 4 To analyze their clonal evolution, we performed a systematic sequencing of the positive PCR fragments at P3 s . An exhaustive set of sequence data at the P0 s/w and the P3 s was generated for eight available matched-samples (Table 2) . Of a total of 79 sequences analyzed on these eight subjects at P3 s , 15 independent BCL2-IGH rearrangements were obtained. Of these, 14 had been already detected at least once either at enrolment (P0 w ) or at the second assessment (P0s) (indicated by a þ in Table 2 ). Conversely, only one new rearrangement (N in Table 2 ) was observed. Importantly, the clonal persistence phenomena was independent of the global t(14;18) frequency level of a given individual. Eventually, eight clones which were found at P0 w or P0 s were not detected anymore at the 3-year follow-up (D in Table 2 ). It is worth noting that most of these were relatively minor clones at enrolment, and might still be present after 3 years (P3 s ), but now falling under the detection threshold used in this study (see Supplementary Information) . This is consistent with the low occurrence of new emerging clones which might also be present under the detection level (#111). Conversely, as shown in Table 2 , the dominance of most major clones remained unchanged since the initial time point. Remarkably, one individual (#120) displayed a 100-fold increase of t(14;18) frequency after 3-years ( Figure 1 ) due to an accumulation of a unique and conserved BCL2-IGH clone (Table 2) . It is worth noting that this individual had received a polyvaccination combining hepatitis C, B, typhoid fever 3 months before the P þ 3 s time point. Altogether, our data indicate that most BCL2-IGH clones are 'long-lived' and persist over several years in the periphery of healthy individuals. To our knowledge, the persistence of identical BCL2-IGH clones over such a long period constitutes an interesting finding which has been described so far in only one individual over a 5-year period. This persistence of clones in healthy individuals is well beyond the average life span of the normal naïve B-lymphocyte pool, which usually display a rapid turnover from few days until few months. Two main, albeit not exclusive, hypotheses can be considered: first, the ectopic level of BCL2 expression conferred by the translocation may contribute to this long life span; this is supported by the extended B-cell survival observed in vivo and in vitro from BCL2-Em transgenic mice. 6 However, the lymphoid hyperplasia described in these mice concerns primarily the splenic B-lineage lymphocytes, and there is no evidence that BCL2 overexpression prolongs the life span of peripheral B-cells, which already physiologically express BCL2 at that stage of differentiation. Thus, the role of a translocation-deregulated BCL2 expression on the long-term persistence of peripheral naïve B-cells remains to be clarified. A second possibility would be that at least some t(14;18)-bearing cells in healthy individuals are 'long-lived' memory, rather than 'naïve' B-cells. Memory B cells are long-lived and proliferating in response to antigen. The recent findings that chronic hepatitis C virus (HCV) infection could promote either the occurrence and/or the maintenance of t(14;18) þ clones in lymphoma-free HCV patients argue toward this possibility. 7 Importantly, an increased prevalence of t(14;18) among HCV-infected patients has been repeatedly observed compared to normal subjects. Moreover, the regression of such t(14;18)-bearing clones was strongly associated with the decrease of viral load in HCV infected patients treated with effective antiviral therapy. 7 This leads to the concept that HCV-related t(14;18) clones need the persistence of an antigenic stimulus to be maintained. Although this issue clearly needs to be confirmed by additional cases, this is in line with our observation of a 100-fold increase of t(14;18) frequency in one individual who experienced a poly-vaccine therapy before blood sampling. In such a scenario, chronic stimulation by low doses of antigens might well account for more subtle maintenance and/or expansion of t(14;18) clones overtime and throughout ageing.
The evidence that long-lived BCL2-IGH clones exist in circulating blood and that their frequency level evolve with ageing raise the question of whether these cells can effectively progress to overt lymphoma. In agreement with many reports, we confirm that BCL2-IGH-clones found in healthy individuals exhibit the same molecular breakpoints features than FL patients: BCL2 breakpoint falling into three main subclusters, a biased usage towards the most external J6 segment, and the presence of an intervening region with N/T nucleotides and few D segments 8 ( Table 2 and data not shown). However, we currently do not know if our detection of identical t(14;18)-clones in peripheral blood of healthy individuals reflects a real maintenance of the same cells in the periphery over time, or represents a dynamic process with recurrent release of t(14;18)-bearing cells from a 'hidden' (pre-malignant?) pool upon antigen reactivation. As BCL2-IGH junctions in healthy individuals cannot be discriminated from those described in FL, 8 further studies are needed to establish whether the t(14;18) detected in healthy individuals occur in a relevant B-cell type, and can effectively be driven into the malignant transformation process. The pathogenic relationship between monoclonal gammopathies of undetermined significance and multiple myeloma represent a typical model illustrating that cells of the relevant lineage (with identical cytogenetic abnormalities and gene expression pattern) could be detected at early steps of the myeloma development (Davies et al., Blood, 2002, 100, 102A, abstract). For the t(14;18) in FL, it is at present difficult to determine the relationship between the presence of this molecular marker and the development of the disease. It therefore, becomes clear that an accurate definition of the B-cell subset carrying the translocation is necessary to provide additional information on the context in which the t(14;18) takes place, on how t(14;18)-bearing cells are maintained, and on the factors that could influence the evolution of such t(14;18) þ clones. from the Ligue Nationale contre le Cancer (Comité de la Manche) and the Conseil Régional de Basse-Normandie. S Roulland 1, 4 , P Lebailly 
